Emgality for migraine in breastfeeding women
Treatments studied
Part of Brain & nervous system clinical trials.
This trial studies how the migraine medication Emgality (galcanezumab) passes into breastmilk and whether it is safe for nursing babies. It may help new mothers who need migraine treatment while breastfeeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 45 years old
- You have been diagnosed with migraines
- You have had a healthy delivery without long-term complications
- Your baby did not need a long stay in the NICU (more than 3 nights)
- You are currently breastfeeding and between 2 weeks and 9 months after giving birth
- You and your doctor have decided that Emgality is a good option for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood samples from people with migraine to find proteins and other markers that might explain why migraines happen. The goal is to better understand migraine, which could help find better treatments in the future.
This observational study looks at health outcomes for moms, babies, and infants after rimegepant is used during pregnancy for migraine. It may help doctors understand potential risks or reassuring safety information for future pregnancies.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This study tracks the health of pregnant women with migraine who take Aimovig. It helps doctors understand if the medicine is safe to use during pregnancy.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This study tests whether rimegepant, a migraine medication, can help prevent migraines in women. It looks at how well it works in real-life settings for women who have frequent migraines.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.